PE20220001A1 - Composiciones que comprenden 5-metoxi-n,n-dimetiltriptamina (5-meo-dmt) para su uso en el tratamiento de trastornos mentales - Google Patents

Composiciones que comprenden 5-metoxi-n,n-dimetiltriptamina (5-meo-dmt) para su uso en el tratamiento de trastornos mentales

Info

Publication number
PE20220001A1
PE20220001A1 PE2021001359A PE2021001359A PE20220001A1 PE 20220001 A1 PE20220001 A1 PE 20220001A1 PE 2021001359 A PE2021001359 A PE 2021001359A PE 2021001359 A PE2021001359 A PE 2021001359A PE 20220001 A1 PE20220001 A1 PE 20220001A1
Authority
PE
Peru
Prior art keywords
dmt
meo
methoxy
treatment
dimethyltriptamine
Prior art date
Application number
PE2021001359A
Other languages
English (en)
Inventor
Theis Terwey
Original Assignee
Gh Res Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gh Res Ireland Limited filed Critical Gh Res Ireland Limited
Publication of PE20220001A1 publication Critical patent/PE20220001A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE AL COMPUESTO 5-METOXI-N,N-DIMETILTRIPTAMINA (5-MEO-DMT) O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO PARA SU USO EN EL TRATAMIENTO DE UN PACIENTE QUE HA SIDO DIAGNOSTICADO CON TRASTORNO DEPRESIVO MAYOR, EN EL QUE EL 5-MEO-DMT SE ADMINISTRA POR VIA INTRAVENOSA, INTRAMUSCULAR O SUBCUTANEA. TAMBIEN SE PROPORCIONAN REGIMENES DE DOSIFICACION PARA TRATAR DICHO TRASTORNO.
PE2021001359A 2019-02-22 2020-02-24 Composiciones que comprenden 5-metoxi-n,n-dimetiltriptamina (5-meo-dmt) para su uso en el tratamiento de trastornos mentales PE20220001A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19158806 2019-02-22
PCT/EP2020/054804 WO2020169851A1 (en) 2019-02-22 2020-02-24 Compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in treating mental disorders

Publications (1)

Publication Number Publication Date
PE20220001A1 true PE20220001A1 (es) 2022-01-05

Family

ID=65529518

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001359A PE20220001A1 (es) 2019-02-22 2020-02-24 Composiciones que comprenden 5-metoxi-n,n-dimetiltriptamina (5-meo-dmt) para su uso en el tratamiento de trastornos mentales

Country Status (19)

Country Link
US (1) US20220031662A1 (es)
EP (1) EP3927338A1 (es)
JP (1) JP2022522659A (es)
KR (1) KR20210154967A (es)
CN (1) CN114423422A (es)
AU (1) AU2020225766A1 (es)
BR (1) BR112021016169A2 (es)
CA (1) CA3130180A1 (es)
CL (1) CL2021002173A1 (es)
CO (1) CO2021010883A2 (es)
CR (1) CR20210436A (es)
DO (1) DOP2021000175A (es)
EA (1) EA202192319A1 (es)
IL (1) IL285539A (es)
MA (1) MA55022A (es)
MX (1) MX2021009942A (es)
NI (1) NI202100074A (es)
PE (1) PE20220001A1 (es)
WO (1) WO2020169851A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210134689A (ko) 2019-02-27 2021-11-10 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
MX2021010198A (es) 2019-02-27 2021-09-21 Univ California Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales.
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
JP7423131B2 (ja) 2019-11-07 2024-01-29 サイビン ユーケー リミテッド 化合物
MX2022014605A (es) 2020-05-19 2022-12-16 Cybin Irl Ltd Derivados de triptamina deuterada y metodos de uso.
US20210378969A1 (en) 2020-06-02 2021-12-09 Small Pharma Ltd. Therapeutic solid dosage forms
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
AU2021289147A1 (en) 2020-06-12 2023-02-02 Beckley Psytech Limited Composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine
CA3188263A1 (en) * 2020-08-05 2022-02-10 Matthias Emanuel LIECHTI Intravenous dmt administration method for dmt-assisted psychotherapy
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
WO2022189662A1 (en) 2021-03-12 2022-09-15 Alvarius Pharmaceuticals Ltd. Compositions and methods for treating addictions comprising 5-meo-dmt
US11602521B2 (en) 2021-04-26 2023-03-14 ATAI Life Sciences AG N,N-dimethyltryptamine compositions and methods
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
WO2023111544A2 (en) * 2021-12-13 2023-06-22 Beckley Psytech Limited Benzoate salt of 5-methoxy-n,n-dimethyltryptamine
WO2023114557A2 (en) * 2021-12-17 2023-06-22 Journey Colab Corp. METHODS OF TREATING SUBSTANCE USE DISORDERS USING 5-MeO-DMT
CA3238440A1 (en) 2021-12-30 2023-07-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
WO2023186831A1 (en) * 2022-03-27 2023-10-05 GH Research Ireland Limited 5-methoxy-n.n-dimethyltryptamine for the treatment of psychomotor retardation
WO2023186826A1 (en) * 2022-03-27 2023-10-05 GH Research Ireland Limited 5-meo-dmt for use in the treatment of postpartum depression
WO2023186834A1 (en) 2022-03-27 2023-10-05 GH Research Ireland Limited Crystalline hydrobromide salt of 5-meo-dmt
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28650A1 (es) * 2003-12-05 2005-02-28 Forest Laboratories Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta
CN103816150A (zh) * 2014-03-14 2014-05-28 兰州理工大学 山蚂蝗生物碱单体成分的用途
US20200147038A1 (en) * 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects

Also Published As

Publication number Publication date
US20220031662A1 (en) 2022-02-03
CO2021010883A2 (es) 2022-01-17
CN114423422A (zh) 2022-04-29
BR112021016169A2 (pt) 2021-11-03
CL2021002173A1 (es) 2022-01-28
CA3130180A1 (en) 2020-08-27
MA55022A (fr) 2021-12-29
EP3927338A1 (en) 2021-12-29
JP2022522659A (ja) 2022-04-20
CR20210436A (es) 2021-11-02
IL285539A (en) 2021-09-30
AU2020225766A1 (en) 2021-08-19
EA202192319A1 (ru) 2021-12-21
DOP2021000175A (es) 2021-11-21
WO2020169851A1 (en) 2020-08-27
NI202100074A (es) 2021-12-06
MX2021009942A (es) 2021-12-10
KR20210154967A (ko) 2021-12-21

Similar Documents

Publication Publication Date Title
PE20220001A1 (es) Composiciones que comprenden 5-metoxi-n,n-dimetiltriptamina (5-meo-dmt) para su uso en el tratamiento de trastornos mentales
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
ECSP22023220A (es) Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
CR20140086A (es) Tratamientos de combinación para hepatitis c
AR090601A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos
JP2016518387A5 (es)
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
EA201892657A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
CO2018009561A2 (es) Métodos para tratar la depresión con antagonistas del receptor de orexina-2
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
MA40769A (fr) Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
CO6220969A2 (es) Adminsitracion semanal de inhibidores de peptidasa de dipeptidilo
CL2021000030A1 (es) Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales
SV2017005595A (es) Unidad de dosificacion orodispersable que contiene un componente estetrol
CL2019003533A1 (es) Uso de vibegron para tratar vejiga sobreactiva.
AR086422A1 (es) Metodo para el tratamiento de tumores solidos avanzados, volasertib
CL2020002544A1 (es) Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret
ES2663836T3 (es) Carboxamidas de quinolina para su uso en el tratamiento de leucemia
CL2020003143A1 (es) Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
ECSP19027578A (es) Composición farmacéutica con antagonista del receptor de mineralocorticoides y su uso
CL2021001635A1 (es) Tratamiento combinado para tumores sólidos con docetaxel y un inhibidor de cyp3a